Manage your personalised Watchlist.Set up an online Virtual Portfolio.Participate in Share Chat.See more trades and director dealings.Play the Fantasy Share Trading Game.
Register for FREE Now
The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Timster
Posted in: AVCT
Posts: 19,018
Price: 47.75
No Opinion
Sounds perfect can we have a worksheet where we have to find test tubes , litmus paper, and big Al's house keys.
How's unfiltering wynbore going?
Price: 48.00
Just what we need, then a Paul hill interview with scripted questions and Paul still shouting over AS.
Price: 48.75
Obviously what can be put on a poster is limited. Thoughts on whether as a supplement we might get the full data to date published, not just snippets.?
Price: 49.00
Agreed he's done feck all in that time.
She definitely says they will be presenting at AACR in April. The transcript probably created automatically and came up with AACI.
Wow what a tweet must be true !
Price: 49.25
Clearly paid actors, the three amigos know what's going on here, should have had a real scientist like eggy on there.
Don't they know the companies going down the pan!
Price: 49.50
There was an RNS the other day, so no news blackout.
How an earth has it taken you this long to come to that conclusion about wynbore?
20p placing inbound?
Price: 51.25
Great news! Avacta due a big rise tomorrow thanks to this news. Well done Hurstbot.
Price: 52.00
We'll look back and laugh when it's £20 by Christmas.
Price: 50.75
You'll be waiting a very long time for an apology. The explainer was "difficult market conditions". The optionality they claimed to have will be swept under the table. Good news is 30 million raised should be see efficacy before they need more money end of 2025
It means phase 1a could have some more seriously impressive efficacy results.
On rocky ground?
No way, I revoke my post!!
Price: 51.00
"Why the ambiguity if not?" This is Avacta 😄
Great sleuthing, does appear he's a very good asset to have with you at AACR. Let's hope Avacta have some side meetings lined up to discuss license options.
Login failed